ArticleDiabetes, obesity & metabolism2026
Dapansutrile preserves pancreatic beta-cell function by regulating insulin vesicle membrane fusion and mitochondrial homeostasis.
Article in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
aims/hypothesisPancreatic beta-cell dysfunction is pivotal in diabetes pathogenesis, with the NOD-like receptor protein 3 (NLRP3) inflammasome playing a crucial role. Dapansutrile (DAPA), a novel NLRP3 inhibitor, demonstrates promise in diabetes management.
methodsThe diabetic model of high-fat diet (HFD) + streptozotocin (STZ) mice was utilized to assess glucose metabolism indicators following DAPA intervention. Experiments involving pancreatic islets from normal mice or humans, as well as INS-1 cell lines, were conducted to evaluate CCK8, glucose-stimulated insulin secretion (GSIS), calcium ion imaging, vesicle fusion and mitochondrial function after exposure to palmitic acid (PA) and DAPA intervention. Additionally, the study explored the efficacy of islet transplantation in type 1 diabetes mice using islets treated with DAPA in vitro.
resultsThis study showed that DAPA improved fasting blood glucose level, glucose tolerance and glucose metabolism in diabetes mice. The experimental work on pancreatic islets and INS-1 cells exposed to PA confirmed that DAPA enhanced GSIS, restored pancreatic function, improved calcium ion flux, mitochondrial dynamics and vesicle fusion. Notably, through the application of pancreatic islet transplantation technology, we illustrated that DAPA effectively addresses systemic glucose metabolism issues at the beta-cell level. CONCLUSIONS/
interpretationDAPA targets the NLRP3 inflammasome in pancreatic beta cells of diabetic mice to preserve function, maintain mitochondrial homeostasis and offer potential avenues for diabetes management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.